Sprekers
- Torfin Aanes, Head of Drug Procurement Cooperation LIS, Norway
- Dr. Hans Ebbers, pharmacist, Utrecht University
- Dr. Anton Franken, specialist internal medicine Isala Zwolle, and member of the Dutch
- Dr. Thijs Giezen, hospital pharmacist, AHZ Haarlem
- Prof.Dr. Joao Goncalves, PharmD, Faculty of Pharmacy, Lisbon – Portugal
- Prof. Geert D’Haens, AMC Amsterdam
- Prof. Dr. Marc Koopmanschap, Department of Health Policy and Management/iMTA, Erasmus University Rotterdam
- Prof Asbjorn Mack, Health Economist LIS, Norway
- Prof.Dr. Ellen Moors, Department of Innovation Studies, Utrecht University
- Dr. Lissy de Ridder, pediatric gastroenterologist, Sophia Children Hospital Rotterdam
- Mathieu Tjoeng PharmD, hospital pharmacist and president Dutch Association of Hospital Pharmacists.
- Dr. Arnold G. Vulto, Professor of Hospital Pharmacy, ErasmusMC Rotterdam
Presentaties
- Dr. Arnold Vulto: Introduction symposium IBN
- Dr. Thijs Giezen: Biosimilars Demystified
- Dr. João Gonçalves: The comparability exercise
- Dr. Hans Ebbers: Extrapolation/ Switching experiences
- Dr. Anton Franken: The Dutch Medicines Board Opinion on Biosimilars
- Dr. Marc Koopmanschap: Pharmacoeconomic potential of biosimilars
- Torfinn Aanes: The Norwegian model regarding expensive medicines and biosimilars
- Asbjørn Mack: How Norway handles the introduction of new expensive drug in the hospital
- Dr. Ellen Moors: Hurdles towards implementation of biosimilars
- Prof. Geert D’Haens: Clinicians’ view on biosimilars: positions by Dutch clinical societies
- Dr. Lissy de Ridder: Clinical research with biosimilars in The Netherlands
- Mathieu Tjoeng: Pharmacovigilance and monitoring requirements for the implementation of biosimilars in the hospital: Databases and patient-registries
- Lonneke Timmers: Summary and Take Home message
Volg ons via: